Cost-effectiveness analyses of breast cancer medications use in developing countries: a systematic review

Al-Ziftawi, Nour Hisham; Shafie, Asrul Akmal; Ibrahim, Mohamed Izham Mohamed

doi:10.1080/14737167.2020.1794826

Cited by 34 publications

(21 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alongside this, there are also concerns generally with the cost of biologicals across a number of Central and Eastern European countries as well as LMICs, which has appreciably limited their prescribing in practice [222][223][224][225][226]. As a result, denying patients access to effective therapies.…”

Section: Biosimilarsmentioning

confidence: 99%

Evidence-based public policy making for medicines across countries: findings and implications for the future

et al. 2021

View full text Add to dashboard Cite

Aim: Global expenditure on medicines is rising up to 6% per year driven by increasing prevalence of non-communicable diseases (NCDs) and new premium priced medicines for cancer, orphan diseases and other complex areas. This is difficult to sustain without reforms. Methods: Extensive narrative review of published papers and contextualizing the findings to provide future guidance. Results: New models are being introduced to improve the managed entry of new medicines including managed entry agreements, fair pricing approaches and monitoring prescribing against agreed guidance. Multiple measures have also successfully been introduced to improve the prescribing of established medicines. This includes encouraging greater prescribing of generics and biosimilars versus originators and patented medicines in a class to conserve resources without compromising care. In addition, reducing inappropriate antibiotic utilization. Typically, multiple measures are the most effective. Conclusion: Multiple measures will be needed to attain and retain universal healthcare.

show abstract

Section: Biosimilarsmentioning

confidence: 99%

Evidence-based public policy making for medicines across countries: findings and implications for the future

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The current situation has already resulted in requests for price moderation for new oncology medicines in countries with high patient co-payment levels [18,19], and this will continue. We are already aware that current prices for new oncology medicines means they will be beyond the reach of the majority of low-and middle-income countries (LMICs) who struggle even to fund trastuzumab [20,21]. This is a concern that needs addressing as LMICs currently witness the fastest growth in mortality from cancer [22,23].…”

Section: Introductionmentioning

confidence: 99%

Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications

Godman

Hill

Simoens

et al. 2021

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

Introduction: There are growing concerns among European health authorities regarding increasing prices for new cancer medicines, prices not necessarily linked to health gain and the implications for the sustainability of their healthcare systems. Areas covered: Narrative discussion principally among payers and their advisers regarding potential approaches to the pricing of new cancer medicines. Expert opinion: A number of potential pricing approaches are discussed including minimum effectiveness levels for new cancer medicines, managed entry agreements, multicriteria decision analyses (MCDAs), differential/tiered pricing, fair pricing models, amortization models as well as de-linkage models. We are likely to see a growth in alternative pricing deliberations in view of ongoing challenges. These include the considerable number of new oncology medicines in development including new gene therapies, new oncology medicines being launched with uncertainty regarding their value, and continued high prices coupled with the extent of confidential discounts for reimbursement. However, balanced against the need for new cancer medicines. This will lead to greater scrutiny over the prices of patent oncology medicines as more standard medicines lose their patent, calls for greater transparency as well as new models including amortization models. We will be monitoring these developments.

show abstract

“…The conclusion of this systematic review was that the use of anti-BC drugs in developing countries is not accompanied by a satisfactory cost/benefit ratio. More and more valid data from developing countries are needed for the evaluation of the pharmacoeconomic parameters of these newly approved drugs [ 74 , 75 , 76 ].…”

Section: Resultsmentioning

confidence: 99%

Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer

Triantafyllidi

Triantafillidis

2022

Biomedicines

View full text Add to dashboard Cite

Trastuzumab is a monoclonal antibody used in the treatment of breast cancer in cases where the tumor overexpresses the HER2 receptor, a cell membrane receptor activated by the epidermal growth factor. Intravenous and subcutaneous administration of trastuzumab have comparable clinical and pharmacological characteristics, but trastuzumab biosimilars are currently only available in intravenous form. Trastuzumab biosimilars are ultimately preferred by a proportion of patients, especially in cases where co-administration of other chemotherapeutic agents, such as trastuzumab and tucatinib, a small molecule of tyrosine kinase inhibitor, is required in patients with HER-positive metastatic breast cancer. Oncologists should be well-aware of the advantages of intravenously administered trastuzumab biosimilars over subcutaneous administration, certainly also taking into account the patient’s preferences. Further cost-effectiveness analyses will be very important, along with expectations regarding successful concomitant subcutaneous administration of trastuzumab with other anticancer drugs, such as pertuzumab. This systematic review describes and analyzes the so-far published studies concerning the use of the available trastuzumab biosimilars in HER-positive early and metastatic breast cancer in terms of efficacy, safety, and cost–benefit ratio. An attempt was also made to draw some conclusions and to comment on future needs and perspectives.

show abstract

Cost-effectiveness analyses of breast cancer medications use in developing countries: a systematic review

Cited by 34 publications

References 40 publications

Evidence-based public policy making for medicines across countries: findings and implications for the future

Evidence-based public policy making for medicines across countries: findings and implications for the future

Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications

Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer

Contact Info

Product

Resources

About